Nitric oxide in the normal kidney and in patients with diabetic nephropathy

Journal of Nephrology

Volumn 28, Issue 3, 2015, Pages 257-268

  Tessari, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Arginine; Diabetes mellitus; Nephropathy; Nitric oxide; Stable isotopes; Vascular disease

Indexed keywords

ALDOSTERONE; ARGININE; C PEPTIDE; N (G), N (G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN ARGININE METHYLTRANSFERASE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIOXIDANT; AUTACOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAS; HYDROGEN SULFIDE; MINERALOCORTICOID ANTAGONIST; PEROXYNITROUS ACID;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; ENDOTHELIUM; GENE EXPRESSION; GENE THERAPY; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASODILATATION; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GAS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; GASES; HUMANS; HYDROGEN SULFIDE; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; KIDNEY; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PEROXYNITROUS ACID; SIGNAL TRANSDUCTION;

EID: 84930199940     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0136-2     Document Type: Review

References (123)

1. Moncada S, Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329(27):2002–2012
2. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789):373–376
3. Förstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33(7):829–837
4. Boudko DY (2007) Bioanalytical profile of the L-arginine/nitric oxide pathway and its evaluation by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 851(1–2):186–210
5. Dejam A, Hunter CJ, Pelletier MM et al (2005) Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood 106(2):734–739
6. Recchia FA, Vogel TR, Hintze TH (2000) NO metabolites accumulate in erythrocytes in proportion to carbon dioxide and bicarbonate concentration. Am J Physiol Heart Circ Physiol 279(2):H852–H856
7. Nathan C, Xie QW (1994) Regulation of biosynthesis of nitric oxide. J Biol Chem 269(19):13725–13728
8. Chen K, Popel AS (2007) Vascular and perivascular nitric oxide release and transport: biochemical pathways of neuronal nitric oxide synthase (NOS1) and endothelial nitric oxide synthase (NOS3). Free Radic Biol Med 42(6):811–822
9. Haque MM, Panda K, Tejero J et al (2007) A connecting hinge represses the activity of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 104(22):9254–9259
10. Mann GE, Yudilevich DL, Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83(1):183–252
11. Montezano AC, Touyz RM (2012) Reactive oxygen species and endothelial function—role of NOS uncoupling and Nox family NADPH oxidases. Basic Clin Pharmacol Toxicol 110(1):87–94
12. Leiper J, Nandi M (2011) The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 10(4):277–291
13. Davids M, Swieringa E, Palm F et al (2012) Simultaneous determination of asymmetric and symmetric dimethylarginine, L-monomethylarginine, L-arginine, and L-homoarginine in biological samples using stable isotope dilution liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 900:38–47
14. López-Jaramillo P, Arenas WD, García RG et al (2008) The role of the L-arginine-nitric oxide pathway in preeclampsia. Ther Adv Cardiovasc Dis 2(4):261–275
15. Leighton F, Urquiaga I (2007) Endothelial nitric oxide synthase as a mediator of the positive health effects of Mediterranean diets and wine against metabolic syndrome. World Rev Nutr Diet 97:33–51
16. Shpektor A (2010) Cardiogenic shock: the role of inflammation. Acute Card Care 12(4):115–118
17. Kayali Z, Herring J, Baron P et al (2009) Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. J Gastroenterol Hepatol 24(6):1030–1037
18. Böger RH, Diemert A, Schwedhelm E et al (2010) The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia. Gynecol Obstet Invest 69(1):1–13
19. Münzel T, Daiber A, Gori T (2011) Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123(19):2132–2144 Review
20. Mount PF, Power DA (2006) Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol (Oxf) 187(4):433–446
21. Rippin JD, Patel A, Belyaev ND et al (2003) Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 46(3):426–428
22. Welch WJ, Wilcox CS (1997) Macula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure. Effects of salt intake. J Clin Invest 100(9):2235–2242
23. Hall CN, Garthwaite J (2009) What is the real physiological NO concentration in vivo? Nitric Oxide 21(2):92–103
24. Brosnan ME, Brosnan JT (2004) Renal arginine metabolism. J Nutrition 134:2791S–2797S
25. Kakoki M, Kim HS, Edgell CJS et al (2006) Amino acids as modulators of endothelium-derived nitric oxide. Am J Physiol Renal Physiol 291(2):F297–F304
26. Wu F, Cholewa B, Mattson DL (2000) Characterization of L-arginine transporters in rat renal inner medullary collecting duct. Am J Physiol Regul Integr Comp Physiol 278(6):R1506–R1512
27. Zoccali C (2007) The endothelium as a target in renal diseases. J Nephrol 20(Suppl 12):S39–S44
28. Lahera V, Salom MG, Miranda-Guardiola F et al (1991) Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 261(6 Pt 2):F1033–F1037
29. Aulak KS, Liu J, Wu J et al (1996) Molecular sites of regulation of expression of the rat cationic amino acid transporter gene. J Biol Chem 271:29799–29806
30. Kakoki M, Kim H-S, Arendshorst W et al (2004) L-Arginine uptake affects nitric oxide production and blood flow in the renal medulla. Am J Physiol Regul Integr Comp Physiol 287(6):R1478–R1485
31. Dallinger S, Sieder A, Strametz J et al (2003) Vasodilator effects of L-arginine are stereospecific and augmented by insulin in humans. Am J Physiol Endocrinol Metab 284(6):E1106–E1106
32. Ruiz M, Singh P, Thomson SC et al (2008) L-arginine-induced glomerular hyperfiltration response: the roles of insulin and ANG-II. Am J Physiol Regul Integr Comp Physiol 294(5):R1744–R1751
33. Rajapakse NW, Mattson DL (2009) Role of L-arginine in nitric oxide production in health and hypertension. Clin Exp Pharm Physiol 36:249–255
34. Gruden G, Viberti G (2005) Pathogenesis of diabetic nephropathy. In: Kahn CR (ed) Joslin’s diabetes mellitus, 14th edn. PA. Lippincott Williams and Wilkins, Philadelphia, pp 853–866
35. Verzola D, Gandolfo MT, Ferrario F et al (2007) Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int 72(10):1262–1272
36. Verzola D, Cappuccino L, D’Amato E, et al. (2014) Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. Kidney Int [Epub ahead of print]
37. Williams ME, Stanton RC (2005) Management of Diabetic Kidney Disease. In: Kahn CR (ed) Joslin’s Diabetes Mellitus, 14th edn. Lippincot Williams & Wilkins, Philadelphia
38. Zelmanovitz T, Gerchman F, Balthazar APS et al (2009) Diabetic nephropathy. Diabetol Metab Syndr 1(1):10
39. Rossing P (2005) The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 48:1439–1444
40. Valmadrid CT, Klein R, Moss SE, Klein BE (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093–1100
41. Amanda Adler I, Richard Stevens J, on behalf of the UKPDS Group et al (2003) Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232
42. American Diabetes Association (2004) Nephropathy in diabetes. Position statement. Diabetes Care 27:s79–s83
43. Reutens AT (2013) Epidemiology of diabetic kidney disease. Med Clin North Am 97(1):1–18
44. Eschwège E (2003) The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab 29(4 Pt 2):6S19–6S27 (Review)
45. Nakagawa T, Segal M, Croker B, Johnson RJ (2007) A breakthrough in diabetic nephropathy: the role of endothelial dysfunction. Nephrol Dial Transplant 22(10):2775–2777
46. Tufro A, Veron D (2012) VEGF and podocytes in diabetic nephropathy. Semin Nephrol 32(4):385–393
47. Valiatti FB, Crispim D, Benfica C et al (2011) The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy. Arq Bras Endocrinol Metab 55(2):106–113
48. Hargrove GM, Dufresne J, Whiteside C et al (2000) Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 58(4):1534–1545
49. Muniyappa R, Quon MJ (2007) Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 10(4):523–530
50. Tessari P, Inchiostro S, Biolo G et al (1991) Effects of acute systemic hyperinsulinemia on forearm muscle proteolysis in healthy man. J Clin Invest 88(1):27–33
51. Tessari P, Biolo G, Inchiostro S et al (1990) Effects of insulin on whole body and forearm leucine and KIC metabolism in type 1 diabetes. Am J Physiol 259(1 Pt 1):E96–E103
52. Zanetti M, Barazzoni R, Kiwanuka E, Tessari P (1999) Effects of branched-chain-enriched amino acids and insulin on forearm leucine kinetics. Clin Sci (Lond) 97(4):437–448
53. Reikerås O, Gunnes P (1986) Effects of high doses of insulin on systemic haemodynamics and regional blood flows in dogs. Clin Physiol 6(2):129–138
54. Brownlee M (1992) Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835–1843 (Review)
55. Selemidis S, Sobey CG, Wingler K et al (2008) NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120(3):254–291 (Review)
56. Tian XY, Wang WT, Xu A et al (2012) Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res 110(9):1211–1216
57. Tomita H, Sanford RB, Smithies O, Kakoki M (2012) The kallikrein-kinin system in diabetic nephropathy. Kidney Int 81(8):733–744
58. Conway BR, Maxwell AP (2009) Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases? Nephron Clin Pract 112(4):c213–c221
59. Dellamea BS, Pinto LC, Leitão CB et al (2014) Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis. BMC Med Genet 15:9
60. Kagawa Y, Cha SH, Hasegawa K et al (1999) Regulation of energy metabolism in human cells in aging and diabetes: FoF(1), mtDNA, UCP, and ROS. Biochem Biophys Res Commun 266(3):662–676
61. Lim SC, Goh SK, Lai YR et al (2006) Relationship between common functional polymorphisms of the p22phox gene (−930 A > G and +242 C > T) and nephropathy as a result of type 2 diabetes in a Chinese population. Diabet Med 23(9):1037–1041
62. Vozarova B, Fernández-Real JM et al (2003) The interleukin-6 (−174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 112(4):409–413
63. Kang P, Tian C, Jia C (2012) Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy. Gene 500(1):1–9
64. Abhary S, Burdon KP, Kuot A et al (2010) Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLoS One 5(3):e9462
65. Tanhäuserová V, Tomand J, Pácal L et al (2012) ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis. Kidney Blood Press Res 36(1):200–208
66. Pieper GM (1999) Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 42(2):204–213
67. Ishii N, Patel KP, Lane PH et al (2001) Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 12(8):1630–1639
68. Komers R, Anderson S (2003) Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 284(6):F1121–F1137
69. Prabhakar SS (2004) Role of nitric oxide in diabetic nephropathy. Semin Nephrol 24(4):333–344
70. Goligorsky MS, Chen J, Brodsky S (2001) Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 37(2 Part 2):744–748
71. Prabhakar S, Starnes J, Shi S et al (2007) Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 18(11):2452–2945
72. Stehouver CD, Henry RM, Dekker JM et al (2004) Microalbuminuria is associated with impaired endothelium dependent, flow mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Study. Kidney Int 92:S42–S44
73. Chu S, Bohlen HG (2004) High concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism. Am J Physiol Renal Physiol 287(3):F384–F392
74. Tessari P, Cecchet D, Cosma A et al (2010) Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy. Diabetes 59(9):2152–2159
75. Avogaro A, Toffolo G, Kiwanuka E et al (2003) L-arginine-nitric oxide kinetics in normal and type 2 diabetic subjects: a stable-labelled 15N arginine approach. Diabetes 52(3):795–802
76. Kashyap SR, Roman LJ, Lamont J et al (2005) Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab 90(2):1100–1105
77. Tessari P, Cecchet D, Artusi C et al (2013) Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo. Diabetes 62(8):2699–2708
78. Badal SS, Danesh FR (2012) Strategies to reverse endothelial dysfunction in diabetic nephropathy. Kidney Int 82(11):1151–1154
79. Noori N, Tabibi H, Hosseinpanah F et al (2013) Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. Int J Vitam Nutr Res 83(2):77–85
80. Imanishi M, Okada N, Konishi Y et al (2013) Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 14(1):67–73
81. Arima S, Kohagura K, Takeuchi K et al (2002) Biphasic vasodilator action of troglitazone on the renal microcirculation. J Am Soc Nephrol 13:342e9
82. Bolignano D, Zoccali C (2012) Glitazones in chronic kidney disease: potential and concerns. Nutr Metab Cardiovasc Dis 22(3):167–175
83. Pistrosch F, Passauer J, Herbrig K et al (2012) Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Horm Metab Res 44(12):914–918
84. Nakamura T, Ushiyama C, Shimada N et al (2000) Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion. In diabetes patients. J Diabetes Complicat 14:250e4
85. Hanefeld M, Brunetti P, Schernthaner GH, QUARTET study group et al (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141e7
86. Sironi AM, Vichi S, Gastaldelli A et al (1997) Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 62:194–202
87. Agarwal R, Saha C, Battiwala M et al (2005) A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 68:285–292
88. Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587–597
89. Hills CE, Brunskill NJ, Squires PE (2010) C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol 31(5):389–397
90. Turgut F, Bolton WK (2010) Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 55(5):928–940
91. Coronel I, Arellano-Mendoza MG, del Valle-Mondragon L et al (2010) L-arginine and antioxidant diet supplementation partially restores nitric oxide-dependent regulation of phenylephrine renal vasoconstriction in diabetics rats. J Ren Nutr 20(3):158–168
92. Klahr S, Morrissey J (2004) L-arginine as a therapeutic tool in kidney disease. Semin Nephrol 24(4):389–394 (Review)
93. Verzola D, Bertolotto MB, Villaggio B et al (2002) Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells. J Investig Med 50(6):443–451
94. Pandya KG, Budhram R, Clark G, Lau-Cam CA (2013) Comparative evaluation of taurine and thiotaurine as protectants against diabetes-induced nephropathy in a rat model. Adv Exp Med Biol 775:371–394
95. Xiao L, Zhu X, Yang S et al (2014) Rap1 ameliorates renal tubular injury in diabetic nephropathy. Diabetes 63(4):1366–1380
96. Yuan F, Liu YH, Liu FY et al (2014) Intraperitoneal administration of the globular adiponectin gene ameliorates diabetic nephropathy in Wistar rats. Mol Med Rep 9(6):2293–2300
97. Matavelli LC, Siragy HM (2013) Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. J Cardiovasc Pharmacol 61(1):17–22
98. Ishizawa K, Izawa-Ishizawa Y, Yamano N et al (2014) Nitrosonifedipine ameliorates the progression of type 2 diabetic nephropathy by exerting antioxidative effects. PLoS One 9(1):e86335
99. Romero MJ, Yao L, Sridhar S et al (2013) l-Citrulline Protects from Kidney Damage in Type 1 Diabetic Mice. Front Immunol 4:480
100. Dessapt-Baradez C, Woolf AS, White KE et al (2014) Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol 25(1):33–42
101. Schildknecht S, Weber A, Gerding HR et al (2013) The NOX1/4 inhibitor GKT136901 as selective and direct scavenger of peroxynitrite. Curr Med Chem 21(3):365–376
102. You H, Gao T, Cooper TK et al (2013) Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int 84(6):1189–1197
103. Gu Y, Gong Y, Zhang H et al (2013) Regulation of transforming growth factor beta 1 gene expression by dihydropteridine reductase in kidney 293T cells. Biochem Cell Biol 91(3):187–193
104. Kidokoro K, Satoh M, Channon KM et al (2013) Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy. J Am Soc Nephrol 24(7):1139–1150
105. Cheng H, Wang H, Fan X et al (2012) Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int 82(11):1176–1183
106. Asakura J, Hasegawa H, Takayanagi K et al (2012) Renoprotective effect of pioglitazone by the prevention of glomerular hyperfiltration through the possible restoration of altered macula densa signaling in rats with type 2 diabetic nephropathy. Nephron Exp Nephrol 122(3–4):83–94
107. Lin M, Yiu WH, Li RX et al (2013) The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int 83(5):887–900
108. Ptilovanciv EO, Fernandes GS, Teixeira LC et al (2013) Heme oxygenase 1 improves glucoses metabolism and kidney histological alterations in diabetic rats. Diabetol Metab Syndr 5(1):3
109. Ojima A, Ishibashi Y, Matsui T et al (2013) Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 182(1):132–141
110. Faria AM, Papadimitriou A, Silva KC et al (2012) Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in experimental diabetes by re-establishing tetrahydrobiopterin levels. Diabetes 61(7):1838–1847
111. Park CH, Noh JS, Tanaka T, Yokozawa T (2012) 7-O-galloyl-D-sedoheptulose ameliorates renal damage triggered by reactive oxygen species-sensitive pathway of inflammation and apoptosis. J Pharm Pharmacol 64(12):1730–1740
112. Kuno Y, Iyoda M, Shibata T et al (2011) Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 162(6):1389–1400
113. Zhou Y, Li JS, Zhang X et al (2010) Ursolic acid inhibits early lesions of diabetic nephropathy. Int J Mol Med 26(4):565–570
114. Schneider MP, Schneider A, Jumar A, et al. (2014) Effects of folic acid on renal endothelial function in patients with diabetic nephropathy: results from a randomized trial. Clin Sci (Lond) [Epub ahead of print]
115. Mose FH, Larsen T, Jensen JM, et al. (2014) Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease. Br J Clin Pharmacol. doi:10.1111/bcp.12390 [Epub ahead of print]
116. Mani S, Cao W, Wu L, et al. (2014) Hydrogen sulfide and the liver. Nitric Oxide. doi:10.1016/j.niox.2014.02.006 [Epub ahead of print] (Review)
117. Altaany Z, Moccia F, Munaron L, et al. (2014) Hydrogen sulfide and endothelial Dysfunction: relationship with nitric oxide. Curr Med Chem [Epub ahead of print]
118. Yuan P, Xue H, Zhou L et al (2011) Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. Nephrol Dial Transplant 26(7):2119–2126
119. Kundu S, Pushpakumar SB, Tyagi A et al (2013) Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9. Am J Physiol Endocrinol Metab 304(12):E1365–E1378
120. Kundu S, Pushpakumar S, Khundmiri SJ, et al. (2014) Hydrogen sulfide mitigates hyperglycemic remodeling via liver kinase B1-adenosine monophosphate-activated protein kinase signaling. Biochim Biophys Acta. pii: S0167-4889(14)00304-8. doi:10.1016/j.bbamcr.2014.08.00
121. Xue H, Yuan P, Ni J et al (2013) H(2)S inhibits hyperglycemia-induced intrarenal renin-angiotensin system activation via attenuation of reactive oxygen species generation. PLoS One 8(9):e74366. doi:10.1371/journal.pone.0074366
122. Andrésdóttir G, Bakker SJ, Hansen HP et al (2013) Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes. Diabet Med 30(5):563–566
123. Mizuno Y, Jacob RF, Mason RP (2010) Advances in pharmacologic modulation of nitric oxide in hypertension. Curr Cardiol Rep 12(6):472–480